To elaborate on how BA exerted its hepatoprotective actions and reduced hepatic steatosis, mechanistic investigations revealed upregulation of the hepatic PPAR-α/p38 signaling axis following BA treatment. The gene discussed is PPARA; the disease is Hepatic steatosis.